Search

Your search keyword '"Troncone, Giancarlo"' showing total 7 results
Start Over Author "Troncone, Giancarlo" Journal british journal of haematology
7 results on '"Troncone, Giancarlo"'

1. Liposomal doxorubicin supercharge‐containing front‐line treatment in patients with advanced‐stage diffuse large B‐cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single‐centre phase II study

Author

Picardi, Marco, primary, Giordano, Claudia, additional, Pugliese, Novella, additional, Esposito, Maria, additional, Fatigati, Melania, additional, Muriano, Francesco, additional, Rascato, Maria G., additional, Della Pepa, Roberta, additional, D'Ambrosio, Alessandro, additional, Vigliar, Elena, additional, Troncone, Giancarlo, additional, Russo, Daniela, additional, Mascolo, Massimo, additional, Esposito, Giovanni, additional, Prastaro, Mariella, additional, Esposito, Roberta, additional, Tocchetti, Carlo G., additional, Fonti, Rosa, additional, Mainolfi, Ciro, additional, Del Vecchio, Silvana, additional, and Pane, Fabrizio, additional

Published
2022
Full Text
View/download PDF

2. Correspondence in reference to the previously published Epub manuscript by Peter Hokland et al . ‘How I treat advanced Hodgkin lymphoma – a global view’. Br J Haematol . 2020;190:837–50

Author

Picardi, Marco, primary, Giordano, Claudia, additional, Della Pepa, Roberta, additional, Pugliese, Novella, additional, Leone, Aldo, additional, Mascolo, Massimo, additional, Daniela, Russo, additional, Vigliar, Elena, additional, Troncone, Giancarlo, additional, Salvatore, Claudia, additional, and Pane, Fabrizio, additional

Published
2021
Full Text
View/download PDF

3. Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma

Author

Della Pepa, Roberta, primary, Picardi, Marco, additional, Giordano, Claudia, additional, Zacheo, Irene, additional, Pugliese, Novella, additional, Cerchione, Claudio, additional, Raimondo, Marta, additional, Di Perna, Maria, additional, Troncone, Giancarlo, additional, Ciancia, Giuseppe, additional, Intrieri, Mariano, additional, and Pane, Fabrizio, additional

Published
2017
Full Text
View/download PDF

5. Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study

Author

Marco Picardi, Claudia Giordano, Novella Pugliese, Maria Esposito, Melania Fatigati, Francesco Muriano, Maria G. Rascato, Roberta Della Pepa, Alessandro D'Ambrosio, Elena Vigliar, Giancarlo Troncone, Daniela Russo, Massimo Mascolo, Giovanni Esposito, Mariella Prastaro, Roberta Esposito, Carlo G. Tocchetti, Rosa Fonti, Ciro Mainolfi, Silvana Del Vecchio, Fabrizio Pane, Picardi, Marco, Giordano, Claudia, Pugliese, Novella, Esposito, Maria, Fatigati, Melania, Muriano, Francesco, Rascato, Maria G, Pepa, Roberta Della, D'Ambrosio, Alessandro, Vigliar, Elena, Troncone, Giancarlo, Russo, Daniela, Mascolo, Massimo, Esposito, Giovanni, Prastaro, Mariella, Esposito, Roberta, Tocchetti, Carlo G, Fonti, Rosa, Mainolfi, Ciro, Del Vecchio, Silvana, and Pane, Fabrizio

Subjects
Adult, c-HL, Hematology, high-dose non-pegylated liposomal doxorubicin, Hodgkin Disease, Polyethylene Glycols, Doxorubicin, Fluorodeoxyglucose F18, Vincristine, DLBCL, Antineoplastic Combined Chemotherapy Protocols, Humans, Prednisone, Lymphoma, Large B-Cell, Diffuse, Rituximab, Cyclophosphamide, R-COMP and MBVD, Etoposide, Neoplasm Staging
Abstract

We evaluated the impact of liposomal doxorubicin (NPLD) supercharge-containing therapy on interim fluorodeoxyglucose positron emission tomography (interim-FDG-PET) responses in high-risk diffuse large B-cell lymphoma (DLBCL) or classical Hodgkin lymphoma (c-HL). In this phase II study (2016-2021), 81 adult patients with advanced-stage DLBCL (n=53) and c-HL (n=28) received front-line treatment with R-COMP-dose-intensified (DI) and MBVD-DI. R-COMP-DI consisted of 70 mg/m2 of NPLD plus standard rituximab, cyclophosphamide, vincristine and prednisone for three cycles (followed by three cycles with NPLD de-escalated at 50 mg/m2 ); MBVD-DI consisted of 35 mg/m2 of NPLD plus standard bleomycin, vinblastine and dacarbazine for two cycles (followed by four cycles with NPLD de-escalated at 25 mg/m2 ). Patients underwent R-COMP-DI and MBVD-DI with a median dose intensity of 91% and 94% respectively. At interim-FDG-PET, 72/81 patients (one failed to undergo interim-FDG-PET due to early death) had a Deauville score of ≤3. At end of treatment, 90% of patients reached complete responses. In all, 20 patients had Grade ≥3 adverse events, and four of them required hospitalisation. At a median 21-months of follow-up, the progression-free survival of the entire population was 77.3% (95% confidence interval 68%-88%). Our data suggest that the NPLD supercharge-driven strategy in high-risk DLBCL/c-HL may be a promising option to test in phase III trials, for improving negative interim-FDG-PET cases incidence.

Published
2022

6. Correspondence in reference to the previously published Epub manuscript by Peter Hokland et al . ‘How I treat advanced Hodgkin lymphoma – a global view’. Br J Haematol . 2020;190:837–50

Author

Giancarlo Troncone, Massimo Mascolo, Russo Daniela, Claudia Salvatore, Aldo Leone, Fabrizio Pane, Marco Picardi, Elena Vigliar, Roberta Della Pepa, Novella Pugliese, Claudia Giordano, Picardi, Marco, Giordano, Claudia, Della Pepa, Roberta, Pugliese, Novella, Leone, Aldo, Mascolo, Massimo, Russo, Daniela, Vigliar, Elena, Troncone, Giancarlo, Salvatore, Claudia, and Pane, Fabrizio

Subjects
medicine.medical_specialty, Lymphoma, business.industry, MEDLINE, medicine, Humans, Hodgkin lymphoma, Hematology, business, Hodgkin Disease, Dermatology
Published
2021

7. Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma

Author

Maria Di Perna, Fabrizio Pane, Giancarlo Troncone, Giuseppe Ciancia, Marco Picardi, Roberta Della Pepa, Claudio Cerchione, Novella Pugliese, Claudia Giordano, Mariano Intrieri, Irene Zacheo, Marta Raimondo, DELLA PEPA, Roberta, Picardi, Marco, Giordano, Claudia, Zacheo, Irene, Pugliese, Novella, Cerchione, Claudio, Raimondo, Marta, DI PERNA, Maria, Troncone, Giancarlo, Ciancia, Giuseppe, Intrieri, Mariano, and Pane, Fabrizio

Subjects
0301 basic medicine, Oncology, Adult, Male, medicine.medical_specialty, Time Factors, Risk Assessment, Maintenance Chemotherapy, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, nodular lymphocyte-predominant Hodgkin lymphoma, Medicine, Humans, Lymphocytes, Aged, business.industry, Remission Induction, risk-adapted therapy, rituximab, Histiocytes, Hematology, Middle Aged, Prognosis, Hodgkin Disease, Survival Analysis, 030104 developmental biology, Treatment Outcome, Nodular Lymphocyte Predominant Hodgkin Lymphoma, 030220 oncology & carcinogenesis, Treatment strategy, Rituximab, Female, business, medicine.drug
Published
2017

Catalog

Books, media, physical & digital resources
See catalog results